KR20250057110A - 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법 - Google Patents
지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법 Download PDFInfo
- Publication number
- KR20250057110A KR20250057110A KR1020257012326A KR20257012326A KR20250057110A KR 20250057110 A KR20250057110 A KR 20250057110A KR 1020257012326 A KR1020257012326 A KR 1020257012326A KR 20257012326 A KR20257012326 A KR 20257012326A KR 20250057110 A KR20250057110 A KR 20250057110A
- Authority
- KR
- South Korea
- Prior art keywords
- conjugate
- cells
- pharmaceutical composition
- formula
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506494P | 2017-05-15 | 2017-05-15 | |
| US62/506,494 | 2017-05-15 | ||
| US201762536966P | 2017-07-25 | 2017-07-25 | |
| US62/536,966 | 2017-07-25 | ||
| US201762582186P | 2017-11-06 | 2017-11-06 | |
| US62/582,186 | 2017-11-06 | ||
| US201862648240P | 2018-03-26 | 2018-03-26 | |
| US62/648,240 | 2018-03-26 | ||
| KR1020197036787A KR102798243B1 (ko) | 2017-05-15 | 2018-05-15 | 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법 |
| PCT/US2018/032817 WO2018213341A1 (en) | 2017-05-15 | 2018-05-15 | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197036787A Division KR102798243B1 (ko) | 2017-05-15 | 2018-05-15 | 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250057110A true KR20250057110A (ko) | 2025-04-28 |
Family
ID=64274790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197036787A Active KR102798243B1 (ko) | 2017-05-15 | 2018-05-15 | 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법 |
| KR1020257012326A Pending KR20250057110A (ko) | 2017-05-15 | 2018-05-15 | 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197036787A Active KR102798243B1 (ko) | 2017-05-15 | 2018-05-15 | 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12036283B2 (enExample) |
| EP (1) | EP3624827A4 (enExample) |
| JP (3) | JP7316222B2 (enExample) |
| KR (2) | KR102798243B1 (enExample) |
| CN (2) | CN119700941A (enExample) |
| AU (2) | AU2018270926C1 (enExample) |
| CA (1) | CA3060410A1 (enExample) |
| IL (2) | IL318018A (enExample) |
| MX (2) | MX2019013621A (enExample) |
| WO (1) | WO2018213341A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202011308VA (en) | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable cytokine polypeptides and methods of use thereof |
| JP7460609B2 (ja) | 2018-05-14 | 2024-04-02 | ウェアウルフ セラピューティクス， インコーポレイテッド | 活性化可能なインターロイキン－２ポリペプチド及びその使用方法 |
| EP3876974A4 (en) * | 2018-11-09 | 2022-11-23 | Nektar Therapeutics | LONG-ACTING INTERLEUKIN-15 RECEPTOR AGONIST IN COMBINATION WITH ANOTHER PHARMACOLOGICALLY ACTIVE AGENT |
| KR20210149090A (ko) * | 2019-04-05 | 2021-12-08 | 넥타르 테라퓨틱스 | 세포 면역요법을 향상시키기 위한 방법 |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| JP7762570B2 (ja) | 2019-05-20 | 2025-10-30 | サイチューン ファーマ | 癌又は感染性疾患を処置するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト投薬レジメン |
| MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| US20230398185A1 (en) | 2020-10-26 | 2023-12-14 | Cytune Pharma | Il-2/il-15r-beta-gamma agonist for treating non-melanoma skin cancer |
| JP2023550685A (ja) | 2020-10-26 | 2023-12-05 | サイチューン ファーマ | 扁平上皮癌を治療するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト |
| JP2024526080A (ja) | 2021-06-23 | 2024-07-17 | サイチューン ファーマ | インターロイキン１５多様体 |
| EP4384204A1 (en) | 2021-08-13 | 2024-06-19 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| AU2024221783A1 (en) * | 2023-02-14 | 2025-07-31 | Akron Bioproducts Llc | Interleukin formulations for in vivo use |
| WO2024215989A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| AU1096595A (en) | 1993-11-12 | 1995-05-29 | Gilead Sciences, Inc. | Thrombin mutants |
| ATE196315T1 (de) | 1994-04-06 | 2000-09-15 | Immunex Corp | Interleukin-15 |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| CA2323048C (en) | 1998-03-12 | 2006-10-10 | Shearwater Polymers, Inc. | Poly(ethylene glycol) derivatives with proximal reactive groups |
| AU2001238595A1 (en) | 2000-02-22 | 2001-09-03 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| JP2006519170A (ja) | 2002-12-26 | 2006-08-24 | マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド | サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体 |
| KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드－종결 중합체 |
| MXPA05007348A (es) | 2003-01-06 | 2005-10-05 | Nektar Therapeutics Al Corp | Derivados de polimeros solubles en agua tiol-selectivos. |
| JP2007506789A (ja) | 2003-09-25 | 2007-03-22 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２１を用いた自己免疫疾患の治療方法 |
| WO2006020849A2 (en) | 2004-08-11 | 2006-02-23 | Beth Israel Deaconess Medical Center, Inc. | Mutant interleukin-15 polypeptides |
| CA2583274A1 (en) | 2004-10-05 | 2007-02-15 | Ochsner Clinic Foundation | Enhancement of b cell proliferation by il-15 |
| US20060257361A1 (en) | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| WO2006138572A2 (en) | 2005-06-16 | 2006-12-28 | Nektar Therapeutics Al, Corporation | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| WO2008106186A2 (en) | 2007-02-28 | 2008-09-04 | Serina Therapeutics, Inc. | Activated polyoxazolines and compositions comprising the same |
| EP2237799B1 (en) | 2008-02-01 | 2019-04-10 | Ascendis Pharma A/S | Prodrug comprising a self-cleavable linker |
| MX2011003117A (es) * | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Conjugados polimericos de peptidos terapeuticos. |
| DK2431741T3 (da) | 2008-10-21 | 2013-10-21 | Baxter Int | Fremgangsmåde til bestemmelse af virksomme bestanddele i profarmaka-PEG-proteinkonjugat |
| KR102325780B1 (ko) | 2010-07-30 | 2021-11-12 | 박스알타 인코퍼레이티드 | 옥심 결합용 친핵성 촉매 |
| RS61854B1 (sr) | 2010-11-12 | 2021-06-30 | Nektar Therapeutics | Konjugati il-2 dela i polimera |
| CN102145178B (zh) * | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| WO2013020079A2 (en) | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
| WO2014201378A1 (en) | 2013-06-13 | 2014-12-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| CN107001438A (zh) | 2014-10-14 | 2017-08-01 | 阿尔莫生物科技股份有限公司 | 白细胞介素‑15组合物及其用途 |
| US12233104B2 (en) * | 2015-10-08 | 2025-02-25 | Nektar Therapeutics | Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist |
-
2018
- 2018-05-15 US US16/613,757 patent/US12036283B2/en active Active
- 2018-05-15 KR KR1020197036787A patent/KR102798243B1/ko active Active
- 2018-05-15 EP EP18803095.1A patent/EP3624827A4/en active Pending
- 2018-05-15 CA CA3060410A patent/CA3060410A1/en active Pending
- 2018-05-15 JP JP2019563255A patent/JP7316222B2/ja active Active
- 2018-05-15 WO PCT/US2018/032817 patent/WO2018213341A1/en not_active Ceased
- 2018-05-15 AU AU2018270926A patent/AU2018270926C1/en active Active
- 2018-05-15 CN CN202411943619.6A patent/CN119700941A/zh active Pending
- 2018-05-15 IL IL318018A patent/IL318018A/en unknown
- 2018-05-15 IL IL270634A patent/IL270634B2/en unknown
- 2018-05-15 CN CN201880032373.3A patent/CN111093688B/zh active Active
- 2018-05-15 KR KR1020257012326A patent/KR20250057110A/ko active Pending
- 2018-05-15 MX MX2019013621A patent/MX2019013621A/es unknown
-
2019
- 2019-11-14 MX MX2024009988A patent/MX2024009988A/es unknown
-
2022
- 2022-05-31 AU AU2022203691A patent/AU2022203691B2/en active Active
-
2023
- 2023-04-10 JP JP2023063333A patent/JP7772733B2/ja active Active
-
2024
- 2024-06-06 US US18/735,818 patent/US20240424115A1/en active Pending
-
2025
- 2025-05-01 JP JP2025076268A patent/JP2025111770A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3624827A1 (en) | 2020-03-25 |
| AU2018270926C1 (en) | 2022-10-27 |
| WO2018213341A1 (en) | 2018-11-22 |
| CN111093688B (zh) | 2025-09-16 |
| US12036283B2 (en) | 2024-07-16 |
| IL270634B1 (en) | 2025-02-01 |
| IL318018A (en) | 2025-02-01 |
| KR20200003922A (ko) | 2020-01-10 |
| KR102798243B1 (ko) | 2025-04-18 |
| CN111093688A (zh) | 2020-05-01 |
| AU2022203691A1 (en) | 2022-06-16 |
| MX2019013621A (es) | 2020-01-13 |
| CA3060410A1 (en) | 2018-11-22 |
| JP7316222B2 (ja) | 2023-07-27 |
| MX2024009988A (es) | 2024-08-27 |
| US20240424115A1 (en) | 2024-12-26 |
| CN119700941A (zh) | 2025-03-28 |
| US20200078467A1 (en) | 2020-03-12 |
| JP2020519676A (ja) | 2020-07-02 |
| AU2018270926B2 (en) | 2022-04-07 |
| EP3624827A4 (en) | 2021-03-03 |
| JP2025111770A (ja) | 2025-07-30 |
| IL270634B2 (en) | 2025-06-01 |
| JP2023082218A (ja) | 2023-06-13 |
| AU2018270926A1 (en) | 2019-11-07 |
| IL270634A (en) | 2019-12-31 |
| AU2022203691B2 (en) | 2023-10-12 |
| JP7772733B2 (ja) | 2025-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102798243B1 (ko) | 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법 | |
| KR102432169B1 (ko) | Ｉｌ-15 부분 및 중합체의 접합체 | |
| JP2018154644A (ja) | Ｉｌ−２部分とポリマーとのコンジュゲート | |
| CA3100204A1 (en) | Compositions of polyethylene glycol conjugates of interleukin-2 and their use to modulate regulatory t cells | |
| EA043667B1 (ru) | Длительно действующие агонисты рецептора интерлейкина-15, связанные с ними композиции и способы их получения и применения | |
| US20250270273A1 (en) | Polymer engineered forms of interferon-gamma and methods of use | |
| HK1235666B (en) | Conjugates of il-15 and branched polyethylene glycol | |
| HK1235666A1 (en) | Conjugates of il-15 and branched polyethylene glycol | |
| HK1190736B (en) | Mono- and di-peg il-10 production and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20250415 Application number text: 1020197036787 Filing date: 20191212 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250507 Comment text: Request for Examination of Application |